RT Journal Article
SR Electronic
T1 Sonodynamic Therapy of Cancer Using Novel Sonosensitizers
JF Anticancer Research
JO Anticancer Res
FD International Institute of Anticancer Research
SP 3673
OP 3677
VO 27
IS 6A
A1 MASAHIDE KUROKI
A1 KEN HACHIMINE
A1 HIRONORI ABE
A1 HIROTOMO SHIBAGUCHI
A1 MOTOMU KUROKI
A1 SHIN-ICHI MAEKAWA
A1 JUN YANAGISAWA
A1 TETSUSHI KINUGASA
A1 TOSHIHIRO TANAKA
A1 YUICHI YAMASHITA
YR 2007
UL http://ar.iiarjournals.org/content/27/6A/3673.abstract
AB Sonodynamic therapy (SDT) of cancer is based on preferential uptake and/or retention of a sonosensitizing drug (sonosensitizer) in tumor tissues and subsequent activation of the drug by ultrasound irradiation. Ultrasound can penetrate deeply into tissues and can be focused into a small region of a tumor to activate a sonosensitizer. This is a unique advantage in the non-invasive treatment of nonsuperficial tumors when compared to laser light used for photodynamic therapy. Recently, it has been found that photochemically active porphyrins also show significant antitumor effects when activated with ultrasound. The mechanism of sonodynamic action has been suggested to involve photoexcitation of the sensitizer by sonoluminescent light, with subsequent formation of singlet oxygen. This mini-review provides a brief overview of the following four sonosensitizers useful in SDT: i) a homogeneous complex of oligomers of hematoporphyrin, Photofrin II; ii) a gallium porphyrin complex, ATX-70; iii) a hydrophilic chlorin derivative, ATX-S10, and iv) a novel porphyrin derivative devoid of photosensitivity, DCPH-P-Na(I). Copyright© 2007 International Institute of Anticancer Research (Dr. John G. Delinassios), All rights reserved